Journal Scans
Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy
Second-Line Therapy for RCC After Failure of VEGF Inhibitor
MM Vickers, TK Choueiri, M Rogers, A Percy, D Finch, I Zama, T Cheng, S North, JJ Knox, C Kollmannsberger, DF McDermott, BI Rini, DY Heng
20100701
2010 Aug 1
Urology
Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy
Urology. 2010 Aug 1;76(2):430-434, MM Vickers, TK Choueiri, M Rogers, A Percy, D Finch, I Zama, T Cheng, S North, JJ Knox, C Kollmannsberger, DF McDermott, BI Rini, DY Heng
TAKE-HOME MESSAGE
Abstract
Abstract
Objectives: To characterize and evaluate the efficacy of second-line therapy in patients who had progressed on initial anti-vascular endothelial growth factor (VEGF) therapy. Methods: Between 2005 and 2007, patients with mRCC who received second-line therapy after 1st-line VEGF-targeted therapy were identified across 7 cancer centers.Results: A total of 645 mRCC patients received first-line VEGF-targeted therapy, of which 216 patients received second-line VEGF-targeted therapy (sunitinib, n = 93;...
